Jeb Keiper
About Jeb Keiper
Jeb Keiper is the CEO of Nimbus Therapeutics, a position he has held since 2018. He has extensive experience in the pharmaceutical industry, having previously worked in various roles at GlaxoSmithKline and McKinsey & Co., and holds multiple degrees from MIT.
Current Role at Nimbus Therapeutics
Jeb Keiper has served as the CEO of Nimbus Therapeutics since 2018. Under his leadership, the company has focused on advancing innovative therapeutics. He previously held the positions of Chief Financial Officer and Chief Business Officer at Nimbus, contributing to the company's strategic direction and financial management.
Previous Experience at GlaxoSmithKline
Keiper worked at GlaxoSmithKline (GSK) in various roles from 2005 to 2014. His positions included Director of R&D Executive Operations, VP of Business Development for GSK Oncology, and Head of Acquisitions and Divestitures. Notably, he led the oncology portion of the GSK-Novartis business swap valued at $16 billion in 2014.
Educational Background and Degrees
Keiper holds four degrees from the Massachusetts Institute of Technology (MIT). He earned a Bachelor of Science in Chemistry, a Master of Science in Chemical Engineering, another Master of Science in Chemical Engineering, and an MBA from the MIT Sloan School of Management. His education has provided a strong foundation for his career in pharmaceuticals and business development.
Board Memberships
Since 2018, Jeb Keiper has been a member of the board at Cardurion Pharmaceuticals, a company focused on cardiovascular diseases. He also serves as a board member at ROME Therapeutics, contributing his expertise in the pharmaceutical sector to both organizations.
Career Beginnings and Early Roles
Keiper began his career as a bench chemist at Pfizer R&D. He later held positions at Massachusetts General Hospital as a Pharmacy Pharmacoeconomic Analyst and at McKinsey & Co. as a Business Analyst and Engagement Manager. These early experiences laid the groundwork for his subsequent roles in business development and executive leadership.